Investigation of V520 in a HIV Vaccine Dose Refinement Study
Phase of Trial: Phase II
Latest Information Update: 27 Aug 2015
At a glance
- Drugs V 520 (Primary)
- Indications HIV infections
- Focus Pharmacodynamics
- Sponsors Merck & Co
- 22 Sep 2007 Status changed from recruiting to discontinued.
- 09 Jan 2007 Status change
- 27 Oct 2006 New trial record.